X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
NATCO PHARMA LIMITED Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

NATCO PHARMA LIMITED  (NTPH)


Here is the latest financial fact sheet of Natco Pharma. For more details, see the Natco Pharma quarterly results and Natco Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
natco pharma - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 927.0       No. of shares m 166.15
    Mkt Cap Rs m 154,013       % ch % -0.8
    Vol '000 22.7       % ch week % -5.5
    P/E X 41.7       % ch 1-mth % 18.3
    P/CF X 119.8       % ch 12-mth % 93.9
    EPS (TTM) Rs 22.2       52 week H/L Rs 1,015.0/440.0
(As on Apr 24, 2017 (Close)) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Mar-10
*
12
Mar-11
*
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs156358361505877 
Low Rs47134197330424 
Sales per share (Unadj.) Rs162.2163.3168.1210.6223.4 
Earnings per share (Unadj.) Rs17.319.019.122.931.1 
Diluted earnings per shareRs2.93.23.64.36.2 
Cash flow per share (Unadj.) Rs24.324.724.230.040.3 
Dividends per share (Unadj.) Rs2.002.003.004.005.00 
Adj. dividends per shareRs0.340.340.560.761.00 
Dividend yield (eoy) %2.00.81.11.00.8 
Book value per share (Unadj.) Rs108.6125.2152.0170.1219.5 
Adj. book value per shareRs18.421.228.532.143.7 
Shares outstanding (eoy) m28.1528.1531.1531.3733.07 
Bonus/Rights/Conversions  ESOP-PPESOPPA 
Price / Sales ratio x0.61.51.72.02.9 
Avg P/E ratio x5.912.914.618.220.9 
P/CF ratio (eoy) x4.210.011.513.916.1 
Price / Book Value ratio x0.92.01.82.53.0 
Dividend payout %11.610.515.717.516.1 
Avg Mkt Cap Rs m2,8576,9258,69113,10021,504 
No. of employees `000NANANANANA 
Total wages/salary Rs m5896648011,0231,128 
Avg. sales/employee Rs ThNMNMNMNMNM 
Avg. wages/employee Rs ThNMNMNMNMNM 
Avg. net profit/employee Rs ThNMNMNMNMNM 
  INCOME DATA
Net Sales Rs m4,5674,5975,2376,6057,389 
Other income Rs m464691124167 
Total revenues Rs m4,6134,6435,3296,7297,556 
Gross profit Rs m9138891,0941,4991,793 
Depreciation Rs m197159159221304 
Interest Rs m130125230263366 
Profit before tax Rs m6326517951,1391,290 
Minority Interest Rs m816116046 
Prior Period Items Rs m-160000 
Extraordinary Inc (Exp) Rs m000-1160 
Tax Rs m137132211364309 
Profit after tax Rs m4875355967191,027 
Gross profit margin %20.019.320.922.724.3 
Effective tax rate %21.620.326.532.023.9 
Net profit margin %10.711.611.410.913.9 
  BALANCE SHEET DATA
Current assets Rs m1,9232,4702,9283,3053,681 
Current liabilities Rs m1,6461,9342,5943,4493,123 
Net working cap to sales %6.111.76.4-2.27.6 
Current ratio x1.21.31.11.01.2 
Inventory Days Days6281778189 
Debtors Days Days4656667259 
Net fixed assets Rs m3,0143,4614,8406,8867,685 
Share capital Rs m282282312314331 
"Free" reserves Rs m2,5363,0054,1384,7686,670 
Net worth Rs m3,0573,5244,7365,3357,259 
Long term debt Rs m5221,2541,3411,378955 
Total assets Rs m5,5437,0739,05210,80411,957 
Interest coverage x5.86.24.55.34.5 
Debt to equity ratio x0.20.40.30.30.1 
Sales to assets ratio x0.80.60.60.60.6 
Return on assets %11.19.39.19.111.7 
Return on equity %15.915.212.613.514.2 
Return on capital %21.116.617.120.120.7 
Exports to sales %21.128.334.242.739.4 
Imports to sales %4.17.07.47.45.7 
Exports (fob) Rs m9641,3011,7902,8172,908 
Imports (cif) Rs m187323388486421 
Fx inflow Rs m9821,3992,1783,2053,445 
Fx outflow Rs m209446570628703 
Net fx Rs m7749531,6082,5772,743 
  CASH FLOW
From Operations Rs m 774 370 649 612 1,440 
From Investments Rs m -609 -888 -1,269 -1,071 -1,089 
From Financial Activity Rs m -342 771 628 263 -353 
Net Cashflow Rs m -176 253 8 -196 -1 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for natco pharma limited

 Share Holding
Indian Promoters : 52.0%
Foreign collaborators : 1.5%
Indian inst/Mut Fund : 7.8%
FIIs : 16.6%
ADR/GDR : 0.0%
Free float : 26.0%
Shareholders : 25,395
Pledged promoter(s) holding : 0.0%
 Company Information
Top
    REGD OFF: NATCO House, Road No.2, Banjara Hills, Hyderabad - 500 033
    E-MAIL: investors@natcopharma.co.in     WEB: www.natcopharma.co.in
    TELEPHONE: (040) 2354 7532     FAX: (040) 2354 8243
    SECTOR: PHARMACEUTICALS     GROUP: MISCELLANEOUS
    TR AGENT: Venture Capital, 12-10-167, Bharatnagar, Hyderabad-500 018
    AUDITOR: Walker, Chandiok & Co.
CHM: V. C. Nannapaneni (MD) COMP SEC: M. Adinarayana YEAR OF INC: 1981 BSE CODE: 524816 FV (Rs): 10 DIV YIELD (%): 0.1

More pharmaceuticals Company Fact Sheets:   WYETH LTDTTK HEALTHCAREPANACEA BIOTECHALKEM LABORATORIESTORRENT PHARMA


Today's Market

Strong Start to the Week; Cement Stocks Rally(Closing)

Share markets in India finished on a strong footing tracking positive trend in global markets after the market's favored candidate, Emmanuel Macron, won the first round of the French presidential election.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Our Private Class with India's Value Investing Guru(The 5 Minute Wrapup)

Apr 19, 2017

Rohan and Kunal present you the discussions with professor Sanjay Bakshi in his virtual classroom.

Why Suddenly There is No Cash in ATMs(Vivek Kaul's Diary)

Apr 11, 2017

There have been a spate of media reports around ATMs not dispensing cash. What is really happening here?

HDFC Bank: The Solid Outperformer(Chart Of The Day)

Apr 22, 2017

Why HDFC Bank beat the Sensex by nearly 3 times.

The Real Reason Indiabulls Real Estate Jumped 42%(Daily Profit Hunter)

Apr 19, 2017

An elephant and six blind men will tell you more about the markets than any financial newspaper or channel.

Is PPF As An Investment Avenue Dead?(Outside View)

Apr 11, 2017

It's true, the interest on PPF has been lowered to 7.9%. PersonalFN evaluates if it's still a promising investment avenue.

More

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON NATCO PHARMA

NATCO PHARMA - ACTAVIS COMPARISON

Compare Company With Charts

COMPARE NATCO PHARMA WITH

MARKET STATS